Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 07, 2024

SELL
$16.75 - $26.1 $299,825 - $467,190
-17,900 Reduced 66.3%
9,100 $226,000
Q4 2023

Feb 14, 2024

BUY
$13.29 - $22.2 $358,830 - $599,400
27,000 New
27,000 $488,000
Q1 2023

May 16, 2023

BUY
$20.02 - $31.37 $150,150 - $235,275
7,500 Added 70.75%
18,100 $384,000
Q4 2022

Feb 14, 2023

BUY
$20.37 - $32.9 $215,922 - $348,740
10,600 New
10,600 $313,000
Q2 2022

Aug 15, 2022

SELL
$12.95 - $46.99 $982,905 - $3.57 Million
-75,900 Reduced 80.57%
18,300 $307,000
Q1 2022

May 16, 2022

BUY
$40.12 - $59.5 $2.65 Million - $3.93 Million
66,000 Added 234.04%
94,200 $4.13 Million
Q4 2021

Feb 14, 2022

BUY
$41.7 - $61.14 $804,810 - $1.18 Million
19,300 Added 216.85%
28,200 $1.72 Million
Q3 2021

Nov 15, 2021

BUY
$27.95 - $44.24 $248,755 - $393,736
8,900 New
8,900 $370,000

Others Institutions Holding BCYC

About BICYCLE THERAPEUTICS plc


  • Ticker BCYC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,676,100
  • Market Cap $647M
  • Description
  • Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...
More about BCYC
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.